SHANGHAI, May 24, 2024
/PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell
Therapeutics), a clinical-stage biotech developing innovative
Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers,
announced latest clinical research results on GC203 (a novel
non-viral vector gene-modified TIL therapy engineered with
membrane-bound IL-7). These data will be presented at the American
Society of Clinical Oncology (ASCO) Annual Meeting taking place on
May 31 - June 4, 2024.
Researchers tested GC203 on patients diagnosed with recurrent
ovarian cancer, without the combination of IL-2 administration or
aggressive lymphodepletion. The objective of the study was to
determine the safety and efficacy of this treatment. A total of 20
patients were enrolled between 09/2021 and 01/2024 in the
open-label single-center trial, in which 18 patients were
evaluable. The evaluable patients were with an ECOG PS of 1 (55.6%)
or 2 (44.4%) and received a median of 5 previous systemic therapies
(range: 2-11). 9 (50%) patients had 3 or more tumor lesions. The
median target lesion size was 57 (range: 13-146) mm.
GC203 showed promising results in patients with recurrent or
metastatic ovarian cancer. The safety profile was improved
significantly compared with conventional TIL therapies, thanks to a
low-intensity pretreatment and the elimination of IL-2 combination.
Most of the Adverse Events (AEs) were grade 1 or grade 2 and could
be alleviated or cured by symptomatic treatment. No grade 5 event
occurred. By the cutoff date of 01/2024, the investigator-assessed
Objective Response Rate (ORR) was 33.3% (95% CI: 16.3 - 56.3),
including 11.1% Complete Response (CR). The Disease Control Rate
(DCR) was 83.3% (95% CI, 60.8 - 94.2). And the 12-month Overall
Survival (OS) rate was 68.8% (95% CI: 49.3 - 95.9). The median OS
was not mature as data cut-off.
Presentation Details
Abstract Number: 5552
Abstract Title: A phase I single-arm, open-label trial of
engineering tumor-infiltrating lymphocytes with membrane-bound lL-7
for recurrent ovarian cancer.
Session Type and Title: Poster Session - Gynecologic
Oncology
Poster Presentation Time: 9:00 AM
- 12:00 PM CDT, June 3,
2024
Presenter: Dr. Jing Guo,
Shanghai Tenth People's Hospital
The abstract is available on the ASCO website.
About Ovarian Cancer
Ovarian cancer has the highest mortality rate among gynecologic
cancers. 70% of patients are diagnosed at an advanced stage. 70% of
patients with advanced ovarian cancer have a survival time of less
than five years. More than 200,000 people worldwide die from
ovarian cancer each year, indicating a significant unmet clinical
need. The primary treatment for advanced ovarian cancer is
platinum-based chemotherapy. Ovarian cancer is insensitive to
immunotherapy, with an ORR of less than 10%. Effective treatment
options are limited.
About GC203
GC203 is a novel non-viral vector gene-modified TIL therapy
developed leveraging Juncell Therapeutics' proprietary
DeepTIL® cell expansion platform and NovaGMP®
gene modification platform. DeepTIL® enables TILs to be
potent enough that no IL-2 combination will be required after
infusion, and the intensity of pretreatment could be lower.
NovaGMP® modifies T cells with a high efficiency
comparable with the Lentiviral vector in an economic way. GC203 is
engineered with self-associating membrane-bound interleukin-7,
which can maintain the stemness of memory T cells, activate
internal immune cells and avoid systemic toxicities.
About Juncell Therapeutics
Juncell Therapeutics is a biotech dedicated to developing
high-quality, accessible TIL cell therapies for the treatment of
solid tumors. Juncell Therapeutics has established its proprietary
DeepTIL® cell expansion and NovaGMP® gene
modification technology platforms, which are designed to address
the key challenges of conventional TIL therapies, making TILs
"robust, competent, affordable, and accessible." Two clinical-stage
TIL therapies have demonstrated promising safety and efficacy in
the treatment of nine types of heavily pretreated advanced solid
tumors, including lung cancer, triple-negative breast cancer,
pancreatic cancer, high-grade glioma, ovarian cancer, endometrial
cancer, cervical cancer, bile duct cancer and melanoma. 7 of these
late-stage tumor patients have achieved CR, and the longest
tumor-free survival time is approaching 3 years.
For more information, please visit:
https://www.juncell.com/en
https://www.linkedin.com/company/juncell-therapeutics
Juncell Contact:
contact@juncell.com
View original
content:https://www.prnewswire.com/news-releases/juncell-therapeutics-announces-clinical-data-of-gc203-til-therapy-in-ovarian-cancer-at-asco-2024-302155132.html
SOURCE Shanghai Juncell Therapeutics Co., Ltd.